It might depend on the proportion of the classical types in each trial. But given the phase 2 trial results I would guess maybe an 85% chance of success for the Lucentis trial and 65% chance for the Eyelea one. ASX continuous disclosure obligations should mean each trial is reported when the results come to hand.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-31
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.035(8.54%) |
Mkt cap ! $547.8M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 45.0¢ | 42.0¢ | $3.084M | 7.074M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 192000 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |